Navigation Links
VIVUS to Present at Lazard Capital Markets Healthcare Conference
Date:11/11/2009

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Lazard Capital Markets 6th Annual Healthcare Conference.

The VIVUS presentation will take place at The St. Regis in New York, NY on Wednesday, November 18, 2009 at 1:45 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.                 Investor Relations: The Trout Group
    Timothy E. Morris                               Brian Korb
    Chief Financial Officer                         646-378-2923
    650-934-5200
                                Media Relations:    Pure Communications, Inc.
                                                    Dan Budwick
                                                    973-271-6085

'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Mich. , May 19 Stryker Corporation (NYSE: ... has informed the Company that the actions undertaken to address issues raised ... , , , ... Warning Letter from FDA regarding compliance with certain quality system requirements at ...
... SAN FRANCISCO, Calif. , May 19 ... studies was published in The Lancet on ... elevated levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific ... coronary heart disease similar in magnitude to that with ...
Cached Medicine Technology:Stryker Announces Resolution of Two FDA Warning Letters 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 3
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... Calif., April 17, 2014 By discovering a new ... after a stroke, researchers at UC Irvine and the ... that may limit or prevent stroke-induced brain damage. , ... fourth-leading cause of death and primary reason for disability ... in a stroke and lets blood-borne material into the ...
(Date:4/17/2014)... online has the potential to ward off depression among ... research published online in The Journals of ... . In the article " Internet Use and Depression ... Longitudinal Analysis ," the authors report that Internet use ... percent among their study sample. , Late-life depression ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... Yarl’s Wood one of the country's biggest immigration detention ... long-term detainees, according to the report of the prison ... launched an inquiry into healthcare at Yarl's Wood Immigration ... treatment of two female asylum seekers from Uganda. ...
... A ban on smoking cigarettes in public places such as ... recommendation// made by a panel consisting of members from the ... that about 3000 to 5000 people exposed to passive smoking ... However a statutory ban on smoking in France could trigger ...
... introduced a new medical device to facilitate the ... ,The Cuban-made equipment, Digital ANGIODIN PD-3000 ... dysfunction and micro and macro vessel failures at ... Tuesday. ,The equipment is simple in ...
... Nobel prize for medicine has been conferred on two Americans, ... of the Harvard University//, for their discovery of ‘RNA interference’, ... humans. , ‘RNA interference’ involves the silencing ... role in the regulation of gene expression, controls the activity ...
... announced on Tuesday the acquisition of Pinewood Laboratories// Limited ... broaden its presence in the European market. ,'This ... over Britain, Ireland and Germany,' Wockhardt chairman Habil Khorakiwala ... million, accounting for almost half of Wockhardt's total sales,' ...
... after the devastating earthquake of 8 October 2005 in ... at risk, facing a second winter without permanent shelter.// ... left around 3.5 million homeless. Estimates have shown that ... while recent landslides and flooding have left most quake ...
Cached Medicine News:Health News:Nobel Prize for Gene ‘Silencing 2Health News:Survivors of Pakistan Earthquake Still at Risk 2
Malaria device / strip (2 line, P.f.-HRP2 Test)...
... Trinity Biotech Uni-Gold™ Pf Malaria Test ... vitro, the presence of Plasmodium ... test is an antigen-capture assay detecting ... histidine- rich protein II (PfHRP- II), ...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Medicine Products: